Targeted therapy of octreotide-modified oleanolic acid liposomes to somatostatin receptor overexpressing tumor cells. (April 2017)

• Record Type: Journal Article
• Authors: Wang, Qianqian; Zhu, Ruiyan; Wang, Meili; Xing, Shanshan; Li, Lei; He, Yuchu; Cao, Weiwei; Gao, Dawei
• Is Part Of: Nanomedicine. Volume 12:Number 8(2017)
• Page Start: 927
• Page End: 940
• Publication Date: 2017-04
• Subjects: antitumor activity -- octreotide -- oleanolic acid -- somatostatin receptor -- targeting transportation; Nanotechnology -- Periodicals; Medical technology -- Periodicals; Nanotechnology -- Therapeutic use -- Periodicals; 610.28
• DOI: 10.2217/nnm-2017-0009
• Languages: English
• ISSNs: 1743-5889

Abstract

Aim: To prepare and validate the efficacy of a novel targeted drug delivery system – octreotide (Oct)-modified oleanolic acid (OA) liposomes.Materials & methods: OA liposomes (OA-L) were prepared by an ethanol injection method. The Oct-modified OA liposomes (O-OA-L) were synthesized and their properties were evaluated. Cellular uptake and competition inhibition studies were performed.Results: The OA vesicles presented satisfactory particles size (100–200 nm), stability and drug release characteristics; their ζ potential was -1.42 ± 0.08 mV. The O-OA-L had a higher cell proliferation inhibitory activity and cellular uptake than that of OA-L for somatostatin receptor-positive A549 cells.Conclusion: The O-OA-L, as a promising agent, can target actively the lesion site with safe and high-efficiency pattern.